Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616734 | 0.89 | FLT3 (0.40) | EIF4A3FLT3KDM4EHPGDHSD17B10 | |
| SCHEMBL19329742 | 0.72 | HRH4 (0.56) | EIF4A3PLGPLAUALOX15FLT3 | |
| SCHEMBL3678805 | 0.72 | HRH4 (0.54) | PLGPLAUFLT3HRH4 | |
| SCHEMBL30344312 | 0.72 | PLG (0.55) | EIF4A3PLGPLAUALOX15FLT3 | |
| SCHEMBL31207838 | 0.72 | HRH4 (0.54) | PLGPLAUFLT3HRH4 | |
| SCHEMBL19687648 | 0.71 | CYP2A6 (0.46) | EIF4A3PLGPLAUALOX15FLT3 | |
| SCHEMBL4741398 | 0.70 | FLT3 (0.59) | EIF4A3PLGPLAUALOX15FLT3 | |
| SCHEMBL8889640 | 0.70 | HRH4 (0.55) | PLGPLAUFLT3HRH4 | |
| SCHEMBL29062810 | 0.70 | ALOX15 (0.64) | ALOX15FLT3KDM4EDAOHPGD | |
| SCHEMBL29540178 | 0.70 | FLT3 (0.59) | PLGPLAUFLT3KDM4EDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794122-B1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7923466-B2 | treating in a lengthening of circadian rhythm period with 6-aminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide; for treating central nervous system diseases and mood disorders, bipolar disorder and sleep disorders, with an enzyme inhibitor | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7629376-B2 | 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-31 | — | — | US | disclosed |
| EP-1794122-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006023467-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK2A3, CSNK1G3, CSNK1G1 | EIF4A3 2490/4885PLG 3395/4885PLAU 3438/4885 |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK1G3, CSNK2A3, CSNK1E | EIF4A3 2453/4885PLG 3595/4885PLAU 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.